Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Sells $1,585,275.04 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kiniksa Pharmaceuticals Price Performance

KNSA stock opened at $24.93 on Friday. The firm has a market capitalization of $1.77 billion, a P/E ratio of 226.64 and a beta of 0.33. The company’s 50 day simple moving average is $24.16 and its 200-day simple moving average is $20.92. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $14.12 and a 52-week high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. The firm had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company’s revenue for the quarter was up 51.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.02) EPS. Sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $32.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at approximately $71,000. Ashton Thomas Private Wealth LLC acquired a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at approximately $100,000. China Universal Asset Management Co. Ltd. increased its stake in Kiniksa Pharmaceuticals by 88.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after buying an additional 3,611 shares during the period. Lynx1 Capital Management LP acquired a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at approximately $177,000. Finally, Arizona State Retirement System acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth $209,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.